CALCIPOTRIENE Drug Patent Profile
✉ Email this page to a colleague
When do Calcipotriene patents expire, and what generic alternatives are available?
Calcipotriene is a drug marketed by Chartwell Rx, Glenmark Speclt, Glenmark Pharms Inc, Cosette, Fougera Pharms, Hikma, Glenmark Pharms Ltd, Padagis Israel, and Taro. and is included in fourteen NDAs.
The generic ingredient in CALCIPOTRIENE is betamethasone dipropionate; calcipotriene. There are sixty-six drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the betamethasone dipropionate; calcipotriene profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CALCIPOTRIENE?
- What are the global sales for CALCIPOTRIENE?
- What is Average Wholesale Price for CALCIPOTRIENE?
Summary for CALCIPOTRIENE
| US Patents: | 0 |
| Applicants: | 9 |
| NDAs: | 14 |
| Finished Product Suppliers / Packagers: | 6 |
| Raw Ingredient (Bulk) Api Vendors: | 51 |
| Clinical Trials: | 38 |
| Patent Applications: | 5,520 |
| Drug Prices: | Drug price information for CALCIPOTRIENE |
| What excipients (inactive ingredients) are in CALCIPOTRIENE? | CALCIPOTRIENE excipients list |
| DailyMed Link: | CALCIPOTRIENE at DailyMed |
Recent Clinical Trials for CALCIPOTRIENE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Cancer Institute (NCI) | Phase 2 |
| Boston University | Phase 2/Phase 3 |
| University of Alabama at Birmingham | Phase 4 |
Pharmacology for CALCIPOTRIENE
| Drug Class | Vitamin D Analog |
Paragraph IV (Patent) Challenges for CALCIPOTRIENE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| DOVONEX | Topical Cream | calcipotriene | 0.005% | 020554 | 1 | 2009-12-02 |
| DOVONEX | Topical Solution | calcipotriene | 0.005% | 020611 | 1 | 2006-05-19 |
US Patents and Regulatory Information for CALCIPOTRIENE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chartwell Rx | CALCIPOTRIENE | calcipotriene | CREAM;TOPICAL | 200935-001 | May 30, 2012 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Fougera Pharms | CALCIPOTRIENE | calcipotriene | SOLUTION;TOPICAL | 078305-001 | May 6, 2008 | AT | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Chartwell Rx | CALCIPOTRIENE | calcipotriene | SOLUTION;TOPICAL | 077029-001 | Nov 20, 2009 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Cosette | CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE | betamethasone dipropionate; calcipotriene | SUSPENSION;TOPICAL | 210765-001 | May 11, 2020 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Hikma | CALCIPOTRIENE | calcipotriene | SOLUTION;TOPICAL | 077579-001 | Nov 19, 2009 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Padagis Israel | CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE | betamethasone dipropionate; calcipotriene | SUSPENSION;TOPICAL | 212367-001 | Sep 11, 2020 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
